started in 2010. Patients from the age of 13 who were questioned about their health behavior and followed up for at least 2 years were selected. HRB were quantified and compared with those of subjects from the general population after matching for age and sex. Data from 2-year follow-up (FU) were used to analyze correlates of multiple risk behavior defined as involvement in two or more risky behaviors. Results: A total of 209 adolescents with JIA (63% female, mean age at baseline 14.4±0.9, mean disease duration 2.6±2.0) and 138 healthy peers (55% female, mean age 14.5±1.0) were included. At baseline, 91% of patients were treated with a DMARD, 21% with a biologic (FU: 59% and 38%). The most common JIA category was rheumatoid factor negative polyarthritis (28%). While at baseline 20% of patients and 4% of controls did not engage in regular physical activity, the proportion at follow-up amounted to 16% and 10%, respectively (OR 3.69; 95%CI: 1.01-13.50). In both groups the proportion of regular smokers, alcohol consumers and drug users increased during the observation period. Significant group differences were found in terms of alcohol consumption and smoking habits, but not in relation to illicit and legal drugs (see table). Patients stated significantly more often that they had not used a condom during their last sexual intercourse (28% vs. 19%, controls, p<0.05). Multiple risk behavior was associated with PedsQL™ total score (OR 0.96; 95%CI: 0.92-0.99) and disease duration (OR 0.75; 95%CI: 0.57-0.98).

Conclusion: Although adolescents with JIA became more physically active during the course of the disease, they are as likely, or more likely, to take risky behaviors than their healthy peers, except for alcohol consumption. In order to achieve optimal outcomes, addressing emotional wellbeing and providing mandatory anticipatory guidance appears to be warranted in this population.

References:

Acknowledgments: ICON is supported by a grant from the German Federal Ministry of Education and Research (FKZ 01 ER 1504A)

Disclosure of Interests: Florian Milatz: None declared, Ina Liedmann: None declared, Martina Niewerth: None declared, Jens Klotzsche: None declared, Gerd Horneff Grant/research support from: AbbVie, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Speakers bureau: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Frank Weller-Heinemann: None declared, Ivan Foedlvari Consultant of: Novartis, Daniel Windischhagen: None declared, Kirsten Minden Consultant of: GlaxoSmithKline, Sanofi, Speakers bureau: Roche

DOI: 10.1136/annrheumdis-2020-eular.2155

THU0513  MEDICATION BURDEN IN YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS – RESULTS OF AN OBSERVATIONAL COHORT STUDY

I. Montag1,2, J. Klotzsche3, M. Niewerth3, S. Tatsis4, E. Seipel5, P. Hoff4, G. Horneff6, K. Minden1,2
1Charité Universitätsmedizin Berlin, Berlin, Germany
2German Rheumatism Research Centre, Berlin, Germany
3Marienkrankenhaus, Hamburg, Germany
4Immanuel Krankenhaus Berlin, Berlin, Germany
5Endokrinologikum Berlin, Berlin, Germany
6Asklepios Kinderklinik Sankt Augustin, Sankt Augustin, Germany

Background: Juvenile idiopathic arthritis (JIA) often persists into adulthood, and many adults with JIA still need antirheumatic medication. Rheumatologists prescribe DMARDs and glucocorticoids, but are not always aware of other medications taken by patients concurrently. Self-reported medication use was used to obtain information on drug exposure of young adults with JIA.

Objectives: To evaluate medication use in a large cohort of young adults with JIA ever treated with DMARDs.

Methods: Patients ever treated with DMARDs and prospectively observed in the JIA biologic registry JuMBO were asked about their drug consumption at each JuMBO visit. In addition, patients reported their current health status in terms of disease activity and pain (scored on numerical rating scales 0-10), functional ability (by HAQ) and quality of life (by SF-36). The Anatomical Therapeutic Chemical Classification System for medicinal products (ATC) was used to classify self-reported medication use. Local therapies, with the exception of ophthalmological drugs, and cough and cold remedies were not included.

Results: A total of 1,306 young adults (68% female) with JIA and a mean disease duration of 13.6±6.9 years (ys) were included in the analysis. The majority of them were classified as polyarticular-onset JIA (35.6%), 20.5% as enthesitis-related arthritis.

At the last follow-up (FU), the patients’ mean age was 23.1±4.1 ys. They had received a mean of 2.6±1.4 DMARDs, 79% were ever treated with biologics. At FU, patients used on average 1.9±1.8 drugs. About one in five patients (296, 22.7%) reported no medication use at all, 367 (28.1%) reported only DMARD use. The most frequently reported drugs were DMARDs (84%), NSAIDs (48%), glucocorticoids (19%), followed by analgesics (10.6%), drugs for acid-related disorders (6.9%) and anti-infectives for systemic use (6.1%). Antidepressant drug use reported 3.4% and antihypertensive drug use 3.1% of the patients. Women used significantly more frequently NSAIDs, glucocorticoids, non-opioid analgesics and thyroid medication. There were 178 (14%) patients who received at least 3 other medications in addition to DMARDs. This patient group frequently reported the use of pain medication (74% NSAIDs, 23% non-opioid analgesics, 20% opioid drugs) and antidepressants (16%) and had been treated late with bDMARDs (7.4±4.9 ys after symptom onset). There were significant differences in drug usage between patients with various JIA categories (table). Moreover, the use of glucocorticoids, antihypertensives and antidepressants in adulthood (adjusted by propensity scores) increased with longer time from symptom onset to bDMARD start.

Conclusion: Self-reported medication use adds important information when assessing the long-term outcome of JIA. About 15% of JIA patients ever exposed to DMARDs, especially those with late start of bDMARD therapy, have a high medication or disease burden in young adulthood.

Acknowledgments: JU-MBO - joint unconditional grant from Pfizer, Abbvie, Roche

Disclosure of Interests: Laura Montag: None declared, Jens Klotzsche: None declared, Martina Niewerth: None declared, Stefanie Tatsis: None declared, Eva Seipel: None declared, Paula Hoff Consultant of: BMS, Amgen, Speakers bureau: Novartis, Jansen, Pfizer, Mylan, BMS, Gerd Horneff Grant/research support from: AbbVie, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Speakers bureau: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Kirsten Minden Consultant of: GlaxoSmithKline, Sanofi, Speakers bureau: Roche

DOI: 10.1136/annrheumdis-2020-eular.1894

THU0514  BIOLOGICAL THERAPY IN JUVENILE PSORIATIC ARTHRITIS – 15 YEARS OF SINGLE CENTER EXPERIENCE

I. Nikishina1, S. Arsenyeva1, M. Kaleida1, A. Shapovalenko1, O. Kostareva1, A. Latypova2, T. Pachorkia2, V.A. Nasonova Research Institute of Rheumatology, Paediatic, Moscow, Russian Federation

Background: Juvenile idiopathic arthritis (JIA) often persists into adulthood, and many adults with JIA still need antirheumatic medication. Rheumatologists prescribe DMARDs and glucocorticoids, but are not always aware of other medications taken by patients concurrently. Self-reported medication use was used to obtain information on drug exposure of young adults with JIA.

Objectives: To evaluate medication use in a large cohort of young adults with JIA ever treated with DMARDs.
Background: Juvenile psoriatic arthritis (JPsA) is one of the clinical variants of juvenile idiopathic arthritis (JIA), which is often characterized by an unfavorable course, refractory to therapy, requiring the prescription of biological agents (BA).

Objectives: analysis of BA use in patients with JPsA and therapy survival, switching to another line of BA.

Methods: the retrospective cohort study included 1095 JIA patients who received BA and were observed in our clinic from 2004 to 2019. All cases of new onset psoriasis were collected; clinical features of disease onset and course, exposure to Methotrexate (MTX) and BA, presence of ANA, HLA B27 were studied.

Results: among 1095 JIA patients who received BA over the past 15 years, a separate cohort of patients with JPsA for analysis was allocated. We identified 50 pts (57% female) aged 2-18 years (Me 13.3) at the time of initiation of therapy. All patients met the JPsA classification criteria, the average age of arthritis onset was 7±4.5 years (ME 6.75). However, cutaneous psoriasis occurred only in 68% (34 pts), with manifestation at the age of 10±5 years. In 25 of 34 pts (73.5%) the development of psoriasis was preceded by joint manifestations in an average of 5±3.8 (ME 3) years. 6 pts from 1095 (0.65%) developed psoriasis under BA therapy: infliximab - 2 cases (0.62/100PY), adalimumab - 3 (0.15/100PY), abatacept - 1 (0.31/100PY). 2/6 pts was ANA+, 3/6 – HLA B27+. Average age of disease onset was 9.8±7.8 years; BA exposure before psoriasis was 2.7±1.1 years and in 3.6±3.4 (ME 1.4) after the onset of arthritis. Therapy was continued in 4/6 pts; switched from infliximab to adalimumab in 2. Seri¬ous comorbid pathology was associated with JPsA in 7 pts (type 1 diabetes mellitus – 2 pts; Down syndrome; endogenous mental illness (schizophrenia); oligophrenia; ovaries polycystic; acute lymphoblastic leukemia in a state of incomplete remission). The clinical picture of the disease was represented by polyarthritis in 84%, oligoarthritis in 8%, the same number of patients 8% had an axial lesion. Sacroiliitis was detected in 20 patients (40%), dactylitis in 21 (42%), and uveitis in 10 (20%). HLA B27 was detected in 16/35 pts (45%), 32% pts were ANA-positive. The duration of the disease at the time of application of the first BA was 5±4 (Me 3.75) years. In 49 patients, BA was used in combina¬tion with methotrexate. The total number of BA courses switching included was 80 (infliximab-19, adalimumab-22, etanercept-27, golimumab-4, abatacept-5, tocilizumab-2, rituximab-1). 49% of patients have experience of using ≥2 BA (16 pts-2 BA, 4 pts-3 BA, 1 pt - 5 BA). Primary/secondary inefficiency (18/35; 51%), adverse events (8/35; 23%), organizational difficulties in market access mostly after the age of 18 (7/35; 20%), and remission (2/35; 6%) were the reasons for the withdrawal of BA. Among the serious adverse events, multi¬ple sclerosis was registered after 6 years of abatacept using (the relationship with the drug used has not been proven), pregnancy in the 3rd year of adal¬imumab use (interruption at 16 weeks); serious local reaction after etanercept use¬ing-1; infusion reactions (1-rituximab, 2-infliximab); uveitis de novo (2- etanercept). Conclusion: JPsA is one of the most severe variants of JIA, characterized by a high proportion of serious comorbid conditions, the development of refrac¬tory or adverse reactions of BA therapy (etanercept, infiximab, adalimumab, et; uveitis, multiple sclerosis, requiring switching to line 2 and 3 with a limited choice of BA with pediatric indications. Special study requires the manifestation of psoriasis de novo mainly developed during TNF-monoclonal antibodies therapy.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6386

Methods: this study was undertaken at Peking Union Medical College Hospital (PUMCH) between 2012 and 2019. Demographic data, clinical presentations and genetic results were collected.

Results: 15 patients had been diagnosed as NLR-related autoinflammatory diseases in our center and to compare the differences of the presentations of CAPS between Chinese and western patients.

Methods: We found 10 NLRP3 mutations, 3 NLRP12 mutations and 1 NLRC4 mutation. There are 3 novel mutations: NLRP3 c.1311G>T, NLRP3 c.1711G>A, and NLRC4 c.514G>A. The major symptoms of those diseases are similar, such as recurrent episodes of fever associated with rash. And some may suffer from arthritis/arthralgia, uveitis, sensorineural deafness, symptoms of central neural systems (CNS). On the other hand, different autoinflammatory diseases have unique characteristics. Symptoms of FACS1, the mildest CAPS disorder, including rash and fever with/ without arthritis/arthralgia, usually develop in the first year of life. The onset age of MWS is 1 to 3 years (8%). In NOMID patients, more likely to develop arthri¬tis/arthralgia, eye involvement, hearing loss and symptoms of CNS. NOMID was the most severe type, and was presented with chronic urticarial-like rash shortly after birth, as well as severe CNS manifestations and musculoskeletal involvement. One of our NOMID patients had clubbing fingers, which was not reported before. The median age of NLRP3-12-AD range from 6 to 5y and the presenta¬tion is similar to MWS while the FCAS4 patient presented with rash and fever, like FACS1.